Safe Harbor Statement

This news release contains forward-looking statements, including statements related to anticipated clinical development, regulatory and commercial milestones and potential health and medical benefits of Soliris® (eculizumab) for the prevention of antibody mediated rejection (AMR) in kidney transplant recipients. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris for its current or potential new indications, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2013 and in our other filings with the US Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

1 Glotz D, Legendre C, Manook M, et al. Eculizumab decreases early antibody-mediated rejection in sensitized deceased donor kidney transplant patients. Presented at the 2013 Congress of the European Society for Organ Transplantation (ESOT), Vienna, Austria, September 10, 2013.

2 LeFaucher C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398-1406.

3 Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033-41.

4 Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10(10):2208-14.

5 Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation—a prospective study. Transplantation 1992;54(4):656-60.

6 Kidney disease statistics for the United States. US Department of Health & Human Services, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC).NIH Publication No. 12–3895; 2012.

7 About CPRA for Professionals. US Department of Health & Human Services, Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/resources/allocationcalculators.asp?index=77. Accessed September 9, 2013.

Copyright Business Wire 2010

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk